EUVIMEDEUVIMED entdecken
Crossref

POU4F1 Promotes the Primary Resistance of Melanoma to Anti‐PD‐1 Therapy by Regulating Glycolysis Through METTL1‐Mediated m7G Methylation of PKM2

Lin Liu, Xiaokang Li, Xinhong Hu, Da Zhai, Tianyu Cao, Ling Liu iD

Molecular Carcinogenesis · 2025-12 · 64 (12) · 2063-2074

DOI: 10.1002/mc.70049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 30.09.2025. Verfasst von Lin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Melanoma, Thyroid Hormones, Immune Checkpoint Inhibitors, Membrane Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: This research was supported by the National Natural Science Foundation of China (Program No. 82203095)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma, a highly malignant tumor originating from melanocytes, has seen a significant increase in global incidence, particularly among the elderly. Anti‐PD‐1 monoclonal antibodies, which activate the immune system to attack cancer cells by blocking the PD‐1/PD‐L1 signaling pathway, have improved survival rates but face challenges such as innate resistance. This study enrolls 37 melanoma patients and 7 benign nevus patients, with tissue samples collected for analysis. RT‐qPCR and Western blot are used to quantify the expression of the target protein. Flow cytometry is utilized to analyze immune subsets in tumors. Glucose uptake, lactate production, and ATP level are assessed by commercial kits. Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) are measured using a Seahorse XF Analyzer. RNA Bisulfite Sequencing is performed to quantify pyruvate kinase M2 (PKM2) m7G methylation level, MeRIP‐qPCR is conducted to validate the m7G methylation level of PKM2, and RIP assay is conducted to confirm POU4F1‐METTL1 interaction. The results show that POU Class 4 Homeobox 1 (POU4F1) is upregulated in melanoma tissues compared to benign nevi. Anti‐PD‐1 treatment effectively reduces POU4F1 expression in sensitive B16‐F10‐M tumors and has no significant effect on resistant B16‐F10‐R tumors. POU4F1 overexpression induces profound metabolic alterations, including increased lactate production, glucose uptake, and ECAR, while suppressing OCR in B16‐F10‐M cells. POU4F1 overexpression also reduces the infiltration of CD8 + T cells, M1‐macrophages, and NK cells, while increasing Treg and M2‐macrophage populations in B16‐F10‐M cells. Importantly, 3‐Bromopyruvate (a glycolysis inhibitor) reverses these effects. Mechanistically, POU4F1 upregulates METTL1 expression and increases m7G methylation of PKM2 mRNA. Besides, there is an interaction between POU4F1 and METTL1. METTL1 is also overexpressed in melanoma tissues compared to benign nevi. In conclusion, POU4F1 drives anti‐PD‐1 resistance in melanoma by enhancing glycolysis via METTL1‐mediated m7G methylation of PKM2. Targeting the POU4F1‐METTL1‐PKM2 axis may improve melanoma immunotherapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaThyroid HormonesImmune Checkpoint InhibitorsMembrane ProteinsDrug Resistance, NeoplasmMethyltransferasesCarrier ProteinsHumansGlycolysisThyroid Hormone-Binding ProteinsMiceProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorGene Expression Regulation, NeoplasticDNA Methylation

Stichwörter der Autor:innen

Anti‐PD‐1 resistanceMETTL1POU4F1m7G methylationmelanoma

Substanzen

Thyroid Hormone-Binding ProteinsThyroid HormonesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorMembrane ProteinsMethyltransferasesPDCD1 protein, humanCarrier Proteins

Autor:innen und Institutionen

  • Department of Dermatology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

ORCID-Profile: Ling Liu

Förderung

  • This research was supported by the National Natural Science Foundation of China (Program No. 82203095).

Zitieren

APA

Liu, L., Li, X., Hu, X., Zhai, D., Cao, T., & Liu, L. (2025). POU4F1 Promotes the Primary Resistance of Melanoma to Anti‐PD‐1 Therapy by Regulating Glycolysis Through METTL1‐Mediated m7G Methylation of PKM2. Molecular Carcinogenesis, 64(12), 2063-2074. https://doi.org/10.1002/mc.70049

Vancouver

Liu L, Li X, Hu X, Zhai D, Cao T, Liu L. POU4F1 Promotes the Primary Resistance of Melanoma to Anti‐PD‐1 Therapy by Regulating Glycolysis Through METTL1‐Mediated m7G Methylation of PKM2. Molecular Carcinogenesis. 2025;64(12):2063-2074. doi:10.1002/mc.70049

BibTeX
@article{Liu2025,
  author = {Liu, Lin and Li, Xiaokang and Hu, Xinhong and Zhai, Da and Cao, Tianyu and Liu, Ling},
  title = {POU4F1 Promotes the Primary Resistance of Melanoma to Anti‐PD‐1 Therapy by Regulating Glycolysis Through METTL1‐Mediated m7G Methylation of PKM2},
  journal = {Molecular Carcinogenesis},
  year = {2025},
  volume = {64},
  number = {12},
  pages = {2063--2074},
  doi = {10.1002/mc.70049}
}
Kostenlos starten →